SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose Reduced Stake in Autolus Therapeutics PLC Below 5%

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a beneficial ownership of 3.8% in Autolus Therapeutics PLC as of March 31, 2025, indicating a passive investment below the 5% threshold.

Summary

• FMR LLC and Abigail P. Johnson jointly filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Autolus Therapeutics PLC.
• As of March 31, 2025, the reporting persons beneficially own 10,162,348 shares of Autolus Therapeutics PLC Common Stock.
• This ownership represents 3.8% of the total outstanding class of securities.
• FMR LLC holds sole voting power and sole dispositive power over all 10,162,348 shares.
• Abigail P. Johnson holds sole dispositive power over the 10,162,348 shares but no sole voting power.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Autolus Therapeutics PLC.
• FMR LLC is classified as a parent holding company, and Abigail P. Johnson is an individual.
• The filing indicates that while other persons may have the right to receive dividends or proceeds from the sale of these securities, no single other person's interest exceeds five percent of the total outstanding common stock.

Sentiment

Score: 4

Explanation: The reduction in stake below 5% by a significant institutional investor like FMR LLC could be perceived negatively by the market, suggesting a decrease in conviction or a reallocation of capital, even if it's a passive filing.

Positives

• The investment is stated to be for ordinary course of business, not for control, which suggests a passive and non-activist stance from this investor.

Negatives

• The beneficial ownership percentage has decreased to 3.8%, suggesting a reduction in stake by FMR LLC and Abigail P. Johnson from a previous position that would have required a 13D or a 13G for greater than 5% ownership.

Future Outlook

This Schedule 13G filing does not provide any forward-looking statements or guidance regarding Autolus Therapeutics PLC's future performance or strategic direction, as it is solely an ownership disclosure.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Autolus Therapeutics PLC.

Industry Context

This filing is a routine disclosure of institutional ownership changes and does not provide broader industry trends or competitive analysis. It reflects a specific investment firm's position in a publicly traded company.

Stakeholder Impact

• Shareholders: May interpret the reduced stake by a major institutional investor as a negative signal, potentially influencing share price due to perceived decreased confidence or capital reallocation.

Key Dates

Recommendation

Keywords

Autolus Therapeutics PLC, FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, institutional investment, SEC filing